Navigation Links
Alpharma Announces Positive Results From Pivotal Phase III Efficacy Trial on ALO-01 (EMBEDA(TM)) (morphine sulfate extended-release with sequestered naltrexone hydrochloride) Capsules at the American Academy of Pain Management Annual Clinical Meeting
Date:9/9/2008

efit to pain patients while delivering peace of mind to physicians and pharmacists," said Joseph Stauffer, D.O., Chief Medical Officer, Senior Vice President of Clinical Research & Medical Affairs, Alpharma Pharmaceuticals. "We look forward to collaborating with the FDA during the review process for ALO-01, which, if approved, would be the first opioid medicine to provide a pharmacologic abuse-deterrent feature while effectively treating patients with chronic pain."

On September 2nd, Alpharma announced that the United States Food and Drug Administration ("FDA") had accepted its New Drug Application ("NDA") for ALO-01 capsules for priority review. The priority review status provides for a review period of six months from the date of submission. The ALO-01 capsule NDA was submitted on June 30, 2008.

In the United States, pain is a serious, undertreated public health problem, with 19 percent of American adults reporting chronic pain and 34 percent reporting recurrent pain.(1A) Opioids provide effective pain management and are especially useful in treating appropriately selected patients with moderate to severe chronic pain who have not responded adequately to other pain management therapies.(2,3A) However, prescription opioid abuse has escalated along with increased legitimate use in pain management.(1B,4A,5) In fact, 70 percent of people who have abused opioids got them from friends and relatives (by stealing, buying, or receiving them).(6) Because of potential prescription opioid abuse, patients and physicians may be reluctant to initiate opioid therapy for pain relief.(4B) Therefore, there is a need for products that deliver effective pain relief while minimizing the potential for misuse, abuse and diversion.(3B,7)

Study Design

The 12-week, double-blind, randomized, placebo-controlled enriched enrollment Phase III pivotal trial assessed the effectiveness of ALO-01 capsules when compared with placebo in 344 adult patients with moderate to
'/>"/>

SOURCE Alpharma Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related medicine technology :

1. Alpharma Presents Data Addressing Abuse Liability Features, Safety and Efficacy on ALO-01 (EMBEDA(TM)) (morphine sulfate extended-release with sequestered naltrexone hydrochloride) at the American Pain Society Annual Scientific Session
2. Dendreon Announces Publication of Phase 1 Study Highlighting Immunologic and Clinical Activity of Lapuleucel-T (Neuvenge(R)) in Advanced Breast Cancer Patients
3. EDAP Announces Launch of Clinical Study Combining HIFU and Chemotherapy for Localized Aggressive High Risk Prostate Cancer
4. Cephalon Announces Positive Results from a Pivotal Study of FENTORA in Opioid-tolerant Patients with Non-cancer Breakthrough Pain
5. ADVENTRX Announces Fast Track Designation Granted By the FDA For CoFactor For the Treatment of Metastatic Colorectal Cancer
6. DOV Pharmaceutical, Inc. Announces Successful Phase Ib Results for DOV 21,947
7. Phosphagenics Announces Positive Phase 1b Transdermal Insulin Clinical Trial Results
8. Xenomics Announces Implementation of its First Diagnostic Test for Acute Myeloid Leukemia Into Clinical Practice
9. Emisphere Technologies, Inc. Announces 2007 Second Quarter Financial Results
10. Amicus Therapeutics Announces Second Quarter 2007 Financial Results
11. Genta Incorporated Announces Second Quarter 2007 Financial Results and Corporate Highlights
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/29/2014)... July 29, 2014 New high priced hepatitis ... D by a projected $2.9 to $5.8 billion next ... firm Milliman released today by the Pharmaceutical Care Management ... could increase by as much as 8.6 percent in ... including Sovaldi and Olysio. The study finds ...
(Date:7/29/2014)... July, 29  2014 ISPE—the International Society for ... John Bournas as President and CEO, succeeding ... leave the Society last fall.  Mr. Bournas takes ... the healthcare association industry as well as significant ... clear vision for the expansion of its global ...
(Date:7/29/2014)... July 29, 2014 /PRNewswire-iReach/ -- MHG Medical Management ... launched its Medical Equipment and X-ray Annual ... are tailored to the cruise industry,s unique requirements.  ... operators to propose that they should develop a ... program is intended to create standardized processes and ...
Breaking Medicine Technology:New Milliman Study: Hepatitis C Drugs Could Increase Medicare Part D Spending by $2.9 to $5.8 Billion in 2015 2ISPE Hires Healthcare Association Exec as CEO 2ISPE Hires Healthcare Association Exec as CEO 3MHG Medical Management Services Aims to Change Cruise Industry Standard With New Equipment Maintenance Program 2
... (NYSE: WPI ), a leading specialty global ... and Chief Executive Officer, will provide an overview and ... Bernstein 28th Annual Strategic Decisions Conference on Wednesday, May ... Hotel in New York, New York.  The presentation will ...
...  Perrigo Company (Nasdaq: PRGO;TASE) today announced that it has ... Administration for its abbreviated new drug application (ANDA) for ... have already begun.  (Logo: http://photos.prnewswire.com/prnh/20120301/DE62255LOGO ... U.S. store brand market is bioequivalent to Novartis, Prevacid® ...
Cached Medicine Technology:Watson to Present at the Sanford C. Bernstein 28th Annual Strategic Decisions Conference 2Perrigo Announces FDA Final Approval and Launch of Store Brand OTC Lansoprazole 15mg Capsules 2
(Date:7/30/2014)... With the accelerated aging of the ... as well as the improved medical care facilities ... industry has been developing quickly, especially in vitro ... in vitro diagnostics market size reached RMB22.98 billion, ... diagnostic reagents. , Chinese in vitro diagnostic ...
(Date:7/30/2014)... Angeles, California (PRWEB) July 30, 2014 ... an online dating community where motorcycle enthusiasts congregate, ... on the site that were revealed by BikerKiss indicate ... increase in the past 3 years. , Members on ... US, UK, Canada, Australia and some other European countries ...
(Date:7/30/2014)... WA (PRWEB) July 30, 2014 According to ... Vkool.com, this is a comprehensive bodybuilding guide for men who ... by up to 50 pounds in within a few ... that will help keep their shoulders healthy and avoid the ... the Critical Bench Program 2.0 uncovers to learners the reason ...
(Date:7/30/2014)... San Diego, CA (PRWEB) July 30, 2014 ... of Melinda J. Helbock A.P.C. are announcing that they are ... from the negative effects of asbestos exposure. , “Symptoms ... that were exposed to the toxin 30 plus years ago ... Melinda Helbock, Founder of The Law Office of Melinda J. ...
(Date:7/30/2014)... TN (PRWEB) July 30, 2014 Regents ... medical imaging services, has brought health care industry veteran ... on board to help lead the company’s ambitious plans ... , “Regents Health has been moving along at a ... to kick it up a notch,” says Bob Maier, ...
Breaking Medicine News(10 mins):Health News:China Diagnostic Reagent Industry (biochemical, molecular & immunodiagnostic) 2016 Forecasts in New Research Report at ChinaMarketResearchReports.com 2Health News:China Diagnostic Reagent Industry (biochemical, molecular & immunodiagnostic) 2016 Forecasts in New Research Report at ChinaMarketResearchReports.com 3Health News:China Diagnostic Reagent Industry (biochemical, molecular & immunodiagnostic) 2016 Forecasts in New Research Report at ChinaMarketResearchReports.com 4Health News:Single Women Motorcycle Riders In Rapid Increase 2Health News:The Critical Bench Program 2.0 Pdf Review Exposes Mike Westerdal's Guide for Increasing Bench Press – Vkool.com 2Health News:The Critical Bench Program 2.0 Pdf Review Exposes Mike Westerdal's Guide for Increasing Bench Press – Vkool.com 3Health News:The Law Office of Melinda J. Helbock A.P.C. Offers Case Evaluations for Possible Asbestos Claims 2Health News:Sferrella and Demonbreun Join Regents Health Resources 2
... the long-term consequences of too much sun exposure can be ... anyone who's spent a day basking on the beach. ,Characterized ... to the touch, sunburn is a sure, almost immediate sign ... been damaged by the sun's ultraviolet rays. And the consequences ...
... havoc on a woman’s bones and a new study reveals ... Researchers know bone loss occurs after menopause, increasing chances of ... and strength. ,The Swedish study involved 146 women who were ... done to determine bone size and density. //All fractures related ...
... week may cut their risk of Alzheimer's by more than ... that diet may affect a person's chances of developing the ... that people 65 and older who had fish once a ... those who never or rarely ate fish. The meals included ...
... you don't use your mind regularly through activities such ... you risk losing some of your cognitive abilities as ... appearing in the June 19 issue of the New ... of Medicine in New York City found seniors who ...
... Clinic in Rochester, Minn., say they have found a ... is an allergic inflammatory reaction of the esophagus. The ... research shows a topical corticosteroid therapy is effective for ... of high levels of eosinophils. Eosinophils are a type ...
... women with colon cancer that has advanced beyond the ... outcome, according to a recent study. In addition to ... may have an increased risk of cancer recurrence, at ... long-term outcomes and treatment-related side effects in colon cancer ...
Cached Medicine News:
Molt periosteal elevator #9, 18.5 cm, 7-1/4"....
Periosteal elevator #9, 18 cm, 7"....
Full curve periosteal elevator - cervical - sharp, round tip, length 184 mm (7 1/4")....
... The Frontier Anterior Deformity System ... Kass, Moss Miami, and Isola ... thoracoscopic procedures to deliver unsurpassed versatility, ... the highest level of versatility for ...
Medicine Products: